Emerging Trends of Probiotics in Formulation Development as a Biotherapeutics Agent


  • SSR College of Pharmacy, Dadra and Nagar Haveli, 396230, India
  • APMC College of Pharmaceutical Education and Research, Himatnagar, 383001, India


Every being wants to live a healthy life. The increase in the discovery and development of medicines is the provoking demand of mankind to meet with the increasing and spreading illness of the society. Pharmaceutical Sciences have proved its worth to meet with the emerging problems with thorough challenges.The concept of probiosis, prebiosis and symbiosis have been recently emerged and being implemented in pharmaceutics to develop, design and delivery of probiotic drugs which can be administered orally as other medicines with its efficient efficacy and least jeopardy.However with the undergoing trends of its designing and discovery, the emphasis has been focused on to its bimolecular mode of action. The present review work would also emphasize the pros and cons of the probiotic food supplements with the necessity for the invention of preceding probiotic drugs which would rapidly pounce, quell and substitute the use of probiotic foods. The idea of this probiotic drug designing will be salutary to the society and would also meet with the cost.


Probiotics, Health Benefit, Formulation Development, Bio-Therapeutics agent.

Subject Discipline

Pharmacy and Pharmacology

Full Text:


Metchnikoff E. “The prolongation of life: optimistic studiesâ€.London: William Heinemann; 1907.

Fuller R. A review: Probiotics in man and animals. J Appl Bacteriol 1989, 66: 365-78.

FAO/WHO. Guidelines for the Evaluation of Probiotics in Food. London Ontario, Canada 2002.

Gosbach S.L, “Probiotics in the Third Milleniumâ€, Digest Liver Dis 2002, 34 (supple.2): S2-7.

Goktepe, I., Juneja, V. K. and Ahmedna, M. Probiotics in food safety and human health. Boca Raton, FL: Taylor and Francis group, 2006.

Guarner F, Malagelada JR. Gut flora in health and disease. Lancet, 2003, 361(9356): 512-9.

Isolauri E, Salminen S. Probiotics: use in allergic disorders: a Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group Report. J Clin Gastroenterol, 2008, 42(Suppl):2:S91-96.

Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Amer J Clin Nutr, 2001, 73(2):444S-450S.

Ruemmele FM, Bier D, Marteau P, Rechkemmer G, Bourdet-Sicard R, Walker WA, Goulet O. Clinical evidence for immunomodulatory effects of probiotic bacteria. J Pediatr Gastroenterol Nutr. 2009, 48(2):126-41.

Salminen S, Benno Y, de Vos W. Intestinal colonisation, microbiota and future probiotics? Asia Pac J Clin Nutr, 2006, 15(4):558-562

Walker Rand M Buckley, Probiotic microbes: The scientific basis. American Academy of Microbiology, Washington DC, 2006, 28 pp.

Ingrassia I, Leplingard A, Darfeuille-Michaud A. Lactobacillus casei DN-114 001 inhibits the ability of adherentinvasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells. Appl Environ Microbiol. 2005, 71(6):2880-2887.

Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, Rizzello F, Campieri M, Brigidi P. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol. 2008, 125(3):28692.

De Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnology. 2008, 111:1-66.

Krishnakumar. Probiotic Cultures – Opportunities and Threats. G IRACT, 2001.

Holzapfel, W. H., Haberer, P., Geisen, R., Bjorkroth, J., and Schillinger, U., Taxonomy and important features of probiotic microorganisms in food and nutrition. Am. J. Clin. Nutr. 2001, 73: 365S-73S.

Barbara Mombelli, Maria Rita Gismondo, The use of probiotics in medical practice, International Journal of Antimicrobial Agents, 2000, 16: 531–536

Aysun Cebeci,Candan G.urakan, Properties of potential probiotic Lactobacillus plantarum strains, Food Microbiology 2003,20: 511–518

MacFie J. et.al., “Probiotics in Clinical Practise:A critical review of the evidence†Nutrition Research,2001, 21: 343–353

Havenaar, R. et al: Selection of strains for probiotics use. Probiotics – The Scientific Basis. 1992, 210-224.

Reid, G., Kim, S. O., & Kohler, G. A., Selecting, testing and understanding probiotic microorganisms. FEMS Immunology and Medical Microbiology, 2006, 46: 149– 157.

Anal, A.K. & Singh, H., Recent advances in microencapsulation of probiotics for industrial applications and targeted delivery. Trends Food Science and Technology, 2007, 18(5): 813 240-251.

Meurman JH, Stamatova I. Probiotics: Contributions to oral health. Oral Dis 2007, 13:443-51

Elina Tuomola, Ross Crittenden, Martin Playne, Erika Isolauri and Seppo Salminen, Quality assurance criteria for probiotic bacteria, American Journal of Clinical Nutrition, February 2001, 73(2): 393S-398s,

United States Pharmacopoeia microbial-limits tests United States Pharmacopoeia. Microbial limits tests. In: United States Pharmacopoeia—National Formulary. 30th ed. Rockville, Maryland: USPC; 2007.

Guidelines and criteria for evaluation of efficacy, safety and health claim of probiotic in food products in India, 2008.

US Food and Drug Administration. Food and drugs: Biologic products: general [600]; Licensing [601]; General biological standards [610]. Code of Federal Regulations title 21, parts 600, 601, and 610. 2006

ICH Expert Working Group. Specifications: test procedures and acceptance criteria for biotechnological/biological products. Guideline Q6B. 2006

Guarner F, Perdigon G, Corthier G, Salminen S, Koletzko B, Morelli L. should yoghurt cultures be considered probiotic? Br J Nutr, 2005, 93(6):783-786.

Gilliland, S.E., Reilly, S.S., Kim, G.B., Kim, H.S. Viability during storage of selected probiotic Lactobacilli and Bifidobacteria in a yogurt like product. J. Fd. Sci. 2002, 67 (8):3091–3095.

Vinderola, C.G., Prosello, W., Ghiberto, T.D. and Reinheimer, J.A. Viability of probiotic (Bifidobacterium, Lactobacillus acidophilus and Lactobacillus casei) and nonprobiotic microflora in Argentinian Fresco cheese. Journal of Dairy Science, 2000, 83: 1905-1911.

Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, Kolacek S, Massar K, Micetic-Turk D, Papadopoulou A, de Sousa JS, Sandhu B, Szajewska H, Weizman Z. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: A multicenter European trial. J Pediatr Gastroenterol Nutr, 2000, 30:54–60.

Szajewska H, Skórka A, Ruszczyński M, Gieruszczak-Białek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther, 2007, 15:25(8):871-881.

Vidhyalakshmi R., Bhakyaraj R. and Subhasre R.S., Encapsulation “The Future of Probioticsâ€-A Review, Advances in Biological Research 2009, 3(3-4): 96-103.

Olejnik A, Lewandowska M, Obarska M, Grajek W. Tolerance of Lactobacillus and Bfidobacterium strains to low pH, bile salts and digestive enzymes. Electronic Journal of Polish Agricultural Universities, Food Science and Technology. 2005, 8 (1):05

Carmen M. et al., In vitro analysis of probiotic strain combinations to inhibit pathogenadhesion to human intestinal mucus, Food Research International, 2007, 40: 629–636

Arthur C. Ouwehanda, Elina M. Tuomolab, Seppo Salminena, Assessment of adhesion properties of novel probiotic strains to human intestinal mucus, International Journal of Food Microbiology, 2001, 64: 119–126

Marteau P. Safety aspects of probiotic products. Scandinavian Journal of Nutrition, 2001, 45:22−30.

Donohue, D.C. Safety of probiotics. Asia Pacific Journal of Clinical Nutrition 2006, 15: 563-569.

Snydman, D.R., The safety of probiotics, Clinical infectious diseases, 2008 46: S104-S111.

Reid, G., Scientific evidence for and against the safe use of probiotics. Trends in Microbiology, 2006, 14: 348–352.

Ishibashi, N., Yamaguchi, S. Probiotics and safety. Amer. J. Clin. Nutr. 2001, 73 (3): 465(S)–470(S).

Liong, M.T., Safety of probiotics: translocation and infection. Nutr Rev, 2008, 66: 192-202.

Saarela M, Mogensen G, Fonden R, Matto J, Mattila-Sandholm T. Probiotic bacteria: Safety, functional and technological properties. J Biotechnol, 2000, 84 (3):197-215.

US Food and Drug Administration. Food and drugs: General biological products standards: Sterility. 2006. Code of Federal Regulations title 21, part 610.12.

Establishing Standards for Probiotic Products: ISAPP’s Role As discussed at the 2004 ISAPP IAC meeting Copper Mountain, Colorado June 22, 2005.

Abe, F., Miyauchi, H., Uchijima, A., Yaeshima, K. and Iwatsuki, K. Stability of bifidobacteria in powdered formula. Inter J Food Sci Tech, 2009b, 44: 718-724.

Abe, F., Tomita, S., Yaeshima, K. and Iwatsuki, K. Effect of production conditions on the stability of a human bifidobacterial species Bifidobacterium longum in yogurt. J Appl Microbiol, 2009c, 49(6):715-20.

Weese JS. Evaluation of deficiencies in labeling of commercial probiotics. Canadian Veterinary Journal, 2003, 44 (12):982-983.


  • There are currently no refbacks.